Signals, Powered By EquityPandit
On Tuesday, the largest drug maker of India, Sun Pharma has said that it has been informed by the USFDA that it is going to lift the import alert imposed on the Mohali manufacturing facility and remove the facility from the official action initiated (OAI) status.
Sun Pharma has said in a statement that “This proposed action will clear the path for Sun Pharma to supply approved products from the Mohali facility to the US market, subject to normal US FDA regulatory requirements.”
The Mohali facility had been inherited by Sun Pharma as part of its acquisition of Ranbaxy Laboratories in 2015.
